Site Search
Results
-
Consumer Products and Therapeutics Program; Julie Foley; BSC...
long term concerns with combination therapies Drinking Water Contaminant Pharma ... Studies of mutual interest . Address concerns of future HIV therapies with clinicians and ...
Size: 1.7MB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/2021/june/presentations/cpt_bsc_presentation_508.pdf -
Minutes: BSC; Nov. 2008
Toxicology Studies 33 VI. DNA-based therapies ......but he wondered if the search for new therapies was based on its carcinogenicity in an ...
Size: 308KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/archives/2008/november/minutes_final.pdf -
RoC Profile: Chlorambucil; 15th RoC 2021
Numerous case reports have linked treatment with chlorambucil, ei- ther alone or in combination with other therapies, with development of cancer, primarily acute nonlymphocytic ...
Size: 121KB https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/content/profiles/chlorambucil.pdf -
Novel Alternative Methods (NAMs) Validation and Qualification...
advance research that will lead to new therapies, diagnostics, and potential cures ... We accelerate prevention, new therapies, diagnostics & potential cures We advance global ...
Size: 3.7MB https://ntp.niehs.nih.gov/sites/default/files/2024-10/2-6_Adam_SACATM2024_508.pdf -
Agenda: BSC; Nov. 20-21, 2008
Edward Carney Criteria for Evaluating Outcomes in Developmental Toxicology Studies (ACTION) . Public Comments . BSC Discussion 3:15 BREAK 3:45 Toxicology of DNA-based Therapies Dr. ...
Size: 78KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/archives/2008/november/bsc_agenda2008nov20_508.pdf -
Agenda: Draft Monograph on Developmental Effects and Pregnancy...
Topoisomerase II Inhibitor Oxygen-free Radical Generator Targeted Therapies Presentation on each mechanism Peer review comments on each agent Panel discussion on each agent Dr. ...
Size: 56KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/monopeerrvw/2012/october/agenda20121002_508.pdf -
Minutes: MPRP; Oct. 1-2, 2012
......... 31 F. Targeted Therapies ......topoisomerase II inhibitors/oxygen free radical generators, and targeted therapies. ...
Size: 559KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/monopeerrvw/2012/october/minutes20121002_508.pdf -
FNIH Overview for ICCVAM (ICCVAM 2024 Public Forum)
advance research that will lead to new therapies, diagnostics, and potential cures. 4 ... We advance global health & seek equity in care We accelerate prevention, new therapies, ...
Size: 4.8MB https://ntp.niehs.nih.gov/sites/default/files/2024-06/14_Conners_ICCVAMPublicForum2024_508.pdf -
Regulatory Applications of 3Rs
The U.S. Food and Drug Administration (FDA) has announced a plan to replace animal testing in the development of monoclonal antibody therapies and other drugs with more effective, ...
https://ntp.niehs.nih.gov/whatwestudy/niceatm/accept-methods/apps -
Speaker Biographies: Collaborative Workshop on Aquatic Models...
... His research involves the development of cell and zebrafish models to study the causes of Parkinson's disease and to develop novel therapies. Dr. Bronstein earned his bachelor's ...
Size: 1.8MB https://ntp.niehs.nih.gov/iccvam/meetings/aquatictox-2014/aquatictox-speakerbios-508.pdf
to Top